Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06697106
Recruiting Not applicable

Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?

NCT06697106 · tracked via the Priya Life Science Egypt tracker
Sponsor
New Valley University
Phase
Not applicable
Started
2024-11-20
Last updated
2024-11-21

Condition(s) studied

COX-2 InhibitorMeloxicamStricture RecurrenceDirect Vision Internal Urethrotomy

Investigational drug(s) / intervention(s)

Nonsteroidal anti-inflammatory drugsPlacebo

Nonsteroidal anti-inflammatory drugs: Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.

Placebo: Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.

Study summary

To evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing urethral stricture recurrence after direct visual internal urethrotomy.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * American Society of Anesthesiologists (ASA) score ≤3. * Urethral stricture length ≤ 1.5 cm Exclusion Criteria: * Recurrent urethral stricture ≥ 2 times. * Pelvic fracture urethral distraction defect (PFUDD).

Primary outcome measure(s)

  • Urethral stricture recurrence — 90 days postoperative
    Urethral stricture recurrence is defined as the need for a secondary procedure, including dilation, internal urethrotomy, and urethroplasty, considered as treatment failure.

Trial sites (1)

FacilityCityRegionStatus
New Valley University New Valley New Valley Governorate Recruiting

More New Valley University trials in Egypt

Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study Recruiting
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification Active, not recruiting
Retroclavicular Block in Vascular Surgey Recruiting
Novel Transdermal Ketoprofen Gel Formulation for Knee Osteoarthritis Active, not recruiting
Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06697106 on ClinicalTrials.gov ↗ ← All trials in Egypt